ArticleAmerican journal of translational research2025
Impact of metoprolol combined with spironolactone on cardiac function in patients with coronary heart disease complicated by heart failure.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metoprolol-spironolactone combination for coronary heart disease with concurrent heart failure: impact on cardiac function.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effect of metoprolol combined with spironolactone on cardiac function in patients with coronary heart disease (CHD) complicated by heart failure.
methodsThe study involved 123 patients with CHD and heart failure treated at Anqing Shihua Hospital of Nanjing Drum Tower Hospital Group between February 2022 and May 2024. After applying the inclusion and exclusion criteria, 100 cases were finally selected. The patients were divided into two groups: the control group (CG, 46 patients), receiving metoprolol monotherapy, and the research group (RG, 54 patients), receiving metoprolol combined with spironolactone. Cardiac function indicators, including left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESd), and left ventricular end-diastolic diameter (LVEDd), were assessed before and after treatment. Additionally, changes in B-type natriuretic peptide (BNP) and C-reactive protein (CRP), cardiac index, and cardiac output were analyzed. The clinical treatment efficacy was also analyzed. Logistic regression analysis was used to identify the risk factors influencing treatment outcomes.
resultsFollowing treatment, both groups showed significant improvements in LVEF (P<0.05) and reductions in LVESd and LVEDd (P<0.05). The RG demonstrated significantly greater improvements in LVEF and more pronounced reductions in LVESd and LVEDd compared to the CG (P<0.05). BNP and CRP levels significantly decreased in both groups (P<0.05), with the RG showing significantly lower levels than the CG (P<0.05). Both cardiac index and cardiac output increased significantly in both groups (P<0.05), with the RG demonstrating notably higher values than the CG (P<0.05). The total effective rate was 69.56% in the CG, significantly lower than 90.74% in the RG (P<0.05). Logistic regression identified age, duration of heart failure, and treatment method as independent risk factors influencing the treatment outcomes (all P<0.05).
conclusionMetoprolol combined with spironolactone significantly improves cardiac function, reduces inflammation, and enhances cardiac performance in patients with CHD complicated by heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.